NPPB and breast carcinoma: In patients with lymphoma or thoracic cancers receiving ≥ 30 Gy to 5% of cardiac volume or mean heart dose (MHD) of ≥ 4 Gy (n = 19, ~ 90% received chemotherapy), Donovan et al. found no association of high-sensitivity (hs) TnI and hsTnT with cardiac dose, and in breast cancer patients treated with hypofractionated radiation (n = 44, ~ 57% received chemotherapy) [47], De Sanctis et al. reported no significant increases in either cTnI or NT-proBNP [48].